Pertactin-Negative and Filamentous Hemagglutinin-Negative *Bordetella pertussis*, Australia, 2013–2017

Zheng Xu, Sophie Octavia, Laurence Don Wai Luu, Michael Payne, Verlaine Timms, Chin Yen Tay, Anthony D. Keil, Vitali Sintchenko, Nicole Guiso, Ruting Lan

During the 2008–2012 pertussis epidemic in Australia, pertactin (Prn)-negative *Bordetella pertussis* emerged. We analyzed 78 isolates from the 2013–2017 epidemic and documented continued expansion of Prn-negative ptX3 B. *pertussis* strains. We also detected a filamentous hemagglutinin-negative and Prn-negative *B. pertussis* isolate.

Despite high vaccination coverage, pertussis remains a major public health concern. In many industrialized countries, including Australia, whole-cell vaccine was replaced by the less reactogenic acellular vaccine (ACV). In Australia, the 3-component ACV (containing pertactin [Prn], pertussis toxin [Ptx], and filamentous hemagglutinin [Fha]) has been more widely used than the 5-component ACV (which also contains fimbrial antigen: Fim2 and Fim3).

Since 1991, when notifications began, pertussis has reemerged in Australia, and epidemics occur every 3–5 years. The largest epidemic occurred in 2008–2012; 39,000 cases were recorded at its peak in 2011 (1,2). Most *Bordetella pertussis* isolates from that epidemic belonged to 1 genetic group, referred to as single-nucleotide polymorphism (SNP) cluster I (I–3). SNP cluster I had prn2 allele of the prn gene and ptX3 allele of the Ptx promoter (3).

In a study of the 2008–2012 epidemic, Lam et al. (1) reported a rapid increase in the number of isolates not expressing the ACV antigen Prn (Prn-negative), from 5.13% in 2008 to 77.78% in 2012. Sequencing of 22 isolates revealed 5 epidemic lineages (ELs) (EL1–EL5) and independent origins of Prn-negative strains in different ELs (4). A smaller epidemic occurred during 2013–2017, peaking at 22,000 cases in 2015 (Figure 1, panel A). We investigated the genotypic and phenotypic characteristics of 78 *B. pertussis* isolates from 2013–2017 to determine the epidemic trends of pertussis in Australia.

The Study

We sequenced 78 *B. pertussis* isolates (Appendix 1 Table 1) from New South Wales (NSW) (17/78 [21.8%]) and Western Australia (WA) (61/78 [78.2%]) that were collected during the 2013–2017 epidemic. We conducted SNP detection (Appendix 1 Table 2) and examined variation in ACV antigen genes (prn, ptX4, ptX5, and the 2 fimbrial genes fim2 and fim3). Using the SNP-based classification scheme by Octavia et al. (5), we typed the 78 isolates into 2 SNP profiles (SPs): SP13 (SNP cluster I, ptX3, prn2, fim2, and fim3) and SP18 (noncluster I, ptX1, prn1, and fim3A). All isolates harbored the ptX1 allele. Most (75/78 [96.2%]) of the SP13 isolates had the prn2 and fim3A alleles. The 3 noncluster I SP18 isolates had a fim3A* allele that differs from fim3A by a synonymous mutation (6) with genotype ptX1-fim3A*-prn1. The frequency of ptX3 and fim3A alleles was higher than during the 2008–2012 epidemic (Figure 1, panels B, C). All but 1 isolate carried the fim2–1 allele. One isolate (L2263 [SP18]) contained a fim2 allele with a new 3-nucleotide insertion (AGA) at position 506, resulting in the insertion of a lysine in the epitope (F2.9) region of Fim2 (5). PROVEAN analysis (6) suggests that the insertion does not affect protein structure and thus might or might not affect immune recognition. We designated this allele as fim2–3 (GenBank accession no. MG824989). Western immunoblotting showed that all isolates expressed PtX, and all but 1 (L2228) expressed Fha. For Prn, 89.7% (70/78) isolates were Prn-negative (Figure 1, panel D), suggesting continued expansion of Prn-negative strains.

We found multiple mechanisms of prn inactivation in the isolates, all but 1 of which were reported previously (1,7–9). For most (66/70) isolates, inactivation was caused by insertion sequences (IS), including 45 IS48F insertions (F/R denotes insertion orientation relative to prn), 17 IS48R insertions, and 4 IS1002R insertions (Table). We found an IS48F insertion, which has been reported in prn1
B. pertussis, Australia

Prn-negative isolate contained a SNP (C→T) in position 223, resulting in a stop codon, a mutation found previously in US isolates only (10). Two isolates had a deletion (position −297, 1325 [relative to the initiation codon ATG]) between the promoter and 5′ end of prn that was replaced with a fragment of IS1663, which might have mediated the deletion (Table). A similar but slightly different deletion (position −292, 1340) was reported in US isolates (7). We identified a new inactivation by a 4-bp deletion, from position 2020 to 2023 in prn, in 1 isolate (L2210) (Appendix 1 Table 1).

Table. Mechanisms of pertactin deficiency and characteristics of Bordetella pertussis isolates from pertussis epidemics, Australia, 2013–2017*

<table>
<thead>
<tr>
<th>Prn deficiency mechanism</th>
<th>Position in pmn†</th>
<th>pmn allele type</th>
<th>State (no. of isolates)</th>
<th>Year (no. isolates)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>IS481F</td>
<td>1613</td>
<td>pm2</td>
<td>Western Australia (32)</td>
<td>2013 (13)</td>
<td>(1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>New South Wales (10)</td>
<td>2014 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015 (11)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2016 (9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2017 (4)</td>
<td></td>
</tr>
<tr>
<td>IS481R</td>
<td>1613</td>
<td>pm2</td>
<td>Western Australia (12)</td>
<td>2013 (6)</td>
<td>(1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>New South Wales (5)</td>
<td>2014 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015 (4)</td>
<td></td>
</tr>
<tr>
<td>IS481F</td>
<td>1598</td>
<td>pm3</td>
<td>Western Australia (3)</td>
<td>2013 (1)</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2014 (2)</td>
<td></td>
</tr>
<tr>
<td>IS7002R</td>
<td>1613</td>
<td>pm2</td>
<td>Western Australia (4)</td>
<td>2013 (2)</td>
<td>(1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2016 (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2017 (1)</td>
<td></td>
</tr>
<tr>
<td>Deletion</td>
<td>−297 to 1325</td>
<td>Not determined‡</td>
<td>Western Australia (2)</td>
<td>2014 (1)</td>
<td>(8), newly found in Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015 (1)</td>
<td></td>
</tr>
<tr>
<td>Stop codon</td>
<td>223</td>
<td>pm2</td>
<td>Western Australia (1)</td>
<td>2014 (1)</td>
<td>(10), newly found in Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015 (1)</td>
<td></td>
</tr>
</tbody>
</table>

*F/R denotes IS insertion orientation relative to pmn. F, forward; IS, insertion sequence; Prn, pertactin; R, reverse.
†The nucleotide positions are relative to the initiation codon (ATG) of the pmn in Tohama I.
‡pmn allele type was not determinable because the repeat regions that define pmn allele type were deleted in this mechanism.
One Prn-negative isolate (L2228) was also Fha-negative (i.e., Prn−, Fha−) by Western immunoblotting. The Fha inactivation probably resulted from changes within the homopolymeric G tract (site: 1078–1087) from 10 Gs to 11 Gs in fhaB, resulting in a downstream stop codon that produces a truncated FhaB protein (11). Both Illumina and Sanger sequencing (Appendix 2) showed a mixture of 10 Gs and 11 Gs. The bacterial population most likely contained predominantly 11 Gs with a lower proportion of 10 Gs. Proteomic analysis using liquid chromatography tandem mass spectrometry (12) found that, in the whole cell of L2228, only 2.3% of the FhaB protein was detected as peptides and derived mainly from the first 350 aa of the FhaB protein. In contrast, in the Fha-positive isolate (L2248), 30.7% of the FhaB protein was detected as peptides and derived from the entire protein. However, in the supernatant of L2228, we detected peptides across the entire FhaB protein and at a higher coverage of 22.7% than for whole-cell FhaB. For the Fha-positive isolate, we detected 52.0% of the FhaB across the entire protein. Western immunoblotting could not detect any FhaB in supernatant or whole-cell proteins of the Fha-negative isolate.

Together with the 27 B. pertussis isolates from Australia previously sequenced, we analyzed a total of 105 B. pertussis isolates to determine their genomic relationships (Figure 2). Five preepidemic SP13 isolates from 1997–2002 were ancestral to the SP13 epidemic clade as expected; 3 noncluster I (ptxP1) isolates grouped together as a separate clade outside SNP cluster I. Most (68/75) isolates grouped into 4 previously defined ELs (EL1–EL4) (4). However, no isolates from the new epidemic fell into the 2008–2012 EL5. Four isolates (L2233, L2234, L2261, and L2262) did not cluster with any of the ELs.

Prn-positive isolates from the 2008–2012 and 2013–2017 epidemics were distributed among different lineages. Prn-negative isolates were largely grouped by mechanism of inactivation in different ELs. Prn-negative isolates in EL1 and EL4 were caused by IS481R insertion. All but 1 Prn-negative isolate in EL2 was caused by IS1002 insertion; the exception was an IS481R insertion. Prn-negative isolates in EL3 were caused by IS481F insertion. Three Prn-negative isolates with new inactivation mechanisms found in Australia were distributed in EL4 (prn::del [-297, 1325]; note that the prn allele was indeterminate) and non-ELs (prn2::stop [C233T]).

EL1 contained isolates from NSW (6/20) and WA (14/20). EL2 was a small lineage (8 isolates), but these isolates were from both periods and both states. EL3 was predominantly a WA lineage; 30/33 isolates from WA and nearly half of the WA isolates (30/61) from 2013–2017 were EL3. EL4 was largely an NSW lineage (14/23 isolates).

Conclusions
The 2013–2017 pertussis epidemic in Australia was predominantly caused by Prn-negative strains, with local and
interstate expansion of 4 epidemic lineages. The ongoing expansion of Prn-negative strains is most likely due to continued vaccine selection pressure because Australia has been using ACVs that contain Prn since their introduction. This observation contrasts with the declining circulation of Prn-negative strains in Japan, where changes in the vaccine probably caused the decrease because 2 of the 3 vaccines used after 2012 did not contain Prn (J3). The emergence of an Fha-negative and Prn-negative B. pertussis in Australia may offer higher potential to escape ACV-induced immunity.

Our results provide further evidence of B. pertussis evolution under vaccine selection. Continued surveillance of B. pertussis will provide a better understanding of the effect of vaccination on the evolution of the pathogen and optimize strategies to reduce the occurrence of pertussis.

Acknowledgments
We thank Narelle Raven for technical assistance.

This study was supported by a grant from the National Health and Medical Research Council of Australia (grant no.1146938). Z.X. is supported by a University of New South Wales scholarship.

About the Author
Ms. Xu is a PhD candidate in the School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia. Her research interests include the epidemiology and evolution of human pathogens.

References

Address for correspondence: Ruiting Lan, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia; email: r.lan@unsw.edu.au
Pertactin-Negative and Filamentous Hemagglutinin-Negative *Bordetella pertussis*, Australia, 2013–2017

Appendix 2

Materials and Methods

Bacterial Strains and Genomic DNA Preparation

*Bordetella pertussis* were sampled from Princess Margaret Hospital for Children, Subiaco WA, and Westmead Hospital, Sydney, NSW, from 2013 to 2017. A total of 78 isolates (details of the strains used in this study are given in Appendix 2 Table 1, https://wwwnc.cdc.gov/EID/article/25/6/18-0240-App1.xlsx) were acquired from cryovials stored in −80°C and inoculated on Bordet Gengou agar (Becton Dickinson, Sparks, MD, USA, supplemented with 7% horse blood). All samples were incubated at 37°C for 4–5 days. Genomic DNA were extracted and purified by the phenol-chloroform method.

Fewer isolates were collected in NSW than WA, possibly due to different numbers of cases coming into the collecting hospital and different uptake of direct PCR as the default method of laboratory diagnosis. The number of isolates did not reflect the population size of the state nor the local incidence of pertussis.

Genome Sequencing and Assembly

Whole-genome sequencing (WGS) of isolates was performed by Illumina MiSeq/NextSeq (Illumina, Scoresby, VIC, Australia). DNA libraries were constructed using Nextera XT Sample preparation kit (Illumina Inc., San Diego, CA, USA). The fragment size distribution of the tagmented DNA was analyzed using a High Sensitivity DNA assay kit (Caliper Life Science, Hopkinton, MA, USA). Genome sequencing was done in a multiplex of 60 samples. Libraries were sequenced either using the MiSeq Personal Sequencer (Illumina Inc) or NextSeq sequencer (Illumina Inc.). Raw reads were submitted to GenBank under the BioProject PRJAN432286). De novo assembly was performed for all sequencing data using
SPAdes (version 3.7.0). Sanger sequencing (ABI 3730 Capillary Sequencer, Ramaciotti Center for Genomics, UNSW Sydney, Kengsinton, NSW, Australia) was performed to confirm the genotypes of prn, fim2, and fhaB. prn was amplified by PCR and sequenced using the published primers (PRN1157 5’-CACCGCAGGCAATGTCAT-3’, PRNBR 5’-CGGATTCAGGCGCAACTC-3’) (1), while newly designed primers (fhaBF 5’-TCAAGTTGGGCACTGGAGAC-3’, fhaBR 5’-CTGGGCTATTTCGACGTGGT-3’) were used for fhaB and (fim2F 5’-ACGGCATTGGCAGTGGTGGA-3’, fim2R 5’-CACACAAACTTGATGGGCGA-3’) for fim2.

**Bioinformatics Analysis**

SNP detection used a combination of mapping by Burrow-Wheeler Alignment (BWA) tool (version 0.7.12), SAMtools (version 0.1.19), and alignment by progressiveMauve (version snapshot_2015_02–25). Phylogenetic trees were constructed using MEGA (version 5.2.1), the Minimum Evolution tree was applied based on the Close-Neighbor-Interchange (CNI) method and the bootstrap analysis was based on 1,000 replicates (SNPs files shown in Appendix 2 Table 2). Short insertion/deletions (indels) (<100 bp) were identified by SAMtools.

**Western Immunoblotting**

Western immunoblotting was used to detect the expression of Pertussis toxin (Ptx), Pertactin (Prn) and Filamentous hemagglutinin (Fha). Bacterial suspensions were mixed with Laemmli buffer (5% β-mercaptoethanol were added before use) and boiled for 10 min. Proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were transferred onto a polyvinylidene difluoride membrane at 100 V for 1.5 hr. Membranes were washed 3 times in washing buffer (50 mM Tris-HCl pH7.6, 150 mM NaCl, 0.05% Tween-20) before incubated, first with blocking buffer (washing buffer, 5% [wt/vol] skim milk powder] at room temperature (RT) for 2 hr, and then with mouse polyclonal antibodies against Ptx, Fha, and Prn (diluted in 1:1,000, 1:1,000, and 1:3,000, respectively with blocking buffer) at 4°C, overnight. After being washed 3 times with washing buffer, membranes were incubated with sheep antimouse (IgG) antibodies conjugated to horse radish peroxidase (Abcam) diluted in 1:20,000 with blocking buffer at RT for 1 hr and 15 min.
Sample Preparation for LC-MS/MS

Liquid chromatography–mass spectrometry (LC-MS/MS) was performed on 2 samples (L2228 and L2248) to confirm the expression of Fha. Each sample had 3 biological repeats. For trypsin digestion, 10 mM Dithiothreitol (DTT) was added to samples (10 μg/sample) for the reduction of disulfide bonds and incubated at 37°C for 30 min. Following incubation, samples were alkylated through the addition of 20 mM Iodoacetamide (IA) and incubated for an additional 30 min at 37°C in the dark. Samples were then incubated at 37°C overnight after Trypsin was added at a ratio of 1:100 enzymes to protein. Strong cationic exchange (SCX) was performed using 200 μL SCX stage tips (Thermo Fisher Scientific) on each sample for clean-up. After SCX, samples were then dried using a Speedivac (Thermo Fisher Scientific) and resuspended in 10 μL of 0.1% formic acid.

LC-MS/MS

Samples were analyzed in the Bioanalytical Mass Spectrometry Facility (BMSF) at the University of New South Wales using LC-MS/MS. Protein identifications were searched against the NCBI database using the Mascot server (v.2.51) (Matrix Science).

Reference

   http://dx.doi.org/10.1128/IAI.69.9.5520-5528.2001